Editor´s Pick

      Rocket Lab Successfully Returns Spacecraft Capsule to Earth, Brings Back Pharmaceuticals Made in Space

      LONG BEACH, Calif.--(BUSINESS WIRE)--Rocket Lab USA, Inc (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a leading launch and space systems company,...

      European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

      BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO®...

      AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

      WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs...

      NorthSea Therapeutics Attains FDA Rare Pediatric Disease Status for SEFA-6179 in Treating Intestinal Failure-Related Liver Disease

      AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and...

      U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1

      PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients ......

      Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

      PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, represent

      Recent Articles